1 / 13

Pieter Cornelis Smits On behalf of all principal COMPARE II investigators:

Pieter Cornelis Smits On behalf of all principal COMPARE II investigators: A. J. van Boven, Mariano Valdes, Antonio Serra, Jean-Jacques Goy, V. Voudris, Ramiro Trillo, J. M. Vazquez, Peter den Heijer, Ton Slagboom, A.G. Vuillomenet.

mheath
Download Presentation

Pieter Cornelis Smits On behalf of all principal COMPARE II investigators:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pieter Cornelis Smits On behalf of all principal COMPARE II investigators: A. J. van Boven, Mariano Valdes, Antonio Serra, Jean-Jacques Goy, V. Voudris, Ramiro Trillo, J. M. Vazquez, Peter den Heijer, Ton Slagboom, A.G. Vuillomenet Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow -up data from COMPARE II study

  2. Potential conflicts of interest Speaker’s name: Pieter C. Smits  I have the following potential conflicts of interest to report:  Research contracts: Boston Scientific, Abbott Vascular, Terumo  Consulting: Blue Medical  Employment in industry; none  Stockholder of a healthcare company; none  Owner of a healthcare company; none  Other(s): travel and speaking fees from Abbott Vascular

  3. COMPARE II trial Multivessel treatment BACKGROUND • The role of percutaneous coronary intervention (PCI) in the treatment of multivessel coronary artery disease (CAD) is still controversial and widely discussed. More liberal use of drug-eluting stents (DES) increased proportion of those patients undergoing PCI procedure, raising a need for more clinical evidence. • The recent reported COMPARE II trial showed similar results of Biolimus-eluting Nobori stent (BES) and Everolimus-eluting Xience/Promus stent (EES) at 1-year in an all comers population. • We aim to compare safety and efficacy outcomes in patients with multivessel CAD (a pre-specified study subset) treated with BES and EES in COMPARE II trial.

  4. COMPARE II trial Multivessel treatment Methodology Total Population: 2.700 patients Randomization 1：2 Non Inferiority Design DAPT up to 12 months 12 sites PI: Dr. P. Smits EES n = 912 BES n = 1795 Patients with Multiple vessels treated (> 1 major coronary artery and/or LM treatment) EES (Multivessel) n =230 BES (Multivessel) n = 453 Clinical Follow-up 0d 30d 3yr 5yr 12mo Primary endpoint at 12 months: Composite ofcardiac death, non-fatal myocardial Infarction and clinically indicated target vessel revascularization

  5. COMPARE II trial Multivessel treatment Baseline Characteristics

  6. COMPARE II trial Multivessel treatment EES BES Clinical Presentation

  7. COMPARE II trial Multivessel treatment Lesion Characteristics

  8. COMPARE II trial Multivessel treatment Lesion Location

  9. COMPARE II trial Multivessel treatment Procedural Characteristics

  10. COMPARE II trial Multivessel treatment Primary Endpoint Composite of Cardiac Death, MI, Clinically Indicated TVR P=NS

  11. COMPARE II trial Multivessel treatment Secondary Endpoint TLF: Composite of Cardiac Death, MI, Clinically Indicated TLR P=NS

  12. COMPARE II trial Multivessel treatment Stent Thrombosis (ARC) (Definite & Probable; ARC Definition)

  13. COMPARE II trial Multivessel treatment Conclusions Although this substudy was not powered to detect differences between the two stents, the BES with biodegradable polymer, was found as safe and effective as the EES even in this challenging patients population. This study adds valuable evidence about clinical outcomes in patients with multivessel disease treated with contemporary DES.

More Related